Agreeing with our findings, Gong et al.229 found that PLAC8 increased PD-L1 expression and conferred tumor resistance to gemcitabine and oxaliplatin, providing an alternative opportunity with PD-1/PD-L1 blockers to treat chemotherapy-refractory patients with GBC. The gene discussed is CD274; the disease is neoplasm.